Nurami Medical Completes Patient Enrollment in ArtiFix® First-in-Human Study
Tuesday, 17 Feb 2026
Nurami Medical Announces Appointment of Erez Rozenfeld as Chairman of the Board
Thursday, 20 Nov 2025
Nurami Medical Announces Successful Completion of Phase 1 Milestones in EIC-Backed Grant for Artifix® Dural Repair Graft
Monday, 16 Jun 2025
Nurami Featured in LSI Weekly Recap
Sunday, 01 Jun 2025
Nurami has closed a Series B Round Led by a Strategic Investor
Monday, 10 Mar 2025
Co-CEO Nora Nseir Featured in Calcalist
Saturday, 13 Jul 2024
Nurami Medical chosen for Blended Financing by the EIC
Tuesday, 02 Jul 2024
Nurami Receives a $4M Investment Grant from the IIA
Monday, 03 Jun 2024
Nurami Accepted to the MedTech Innovator Program
Thursday, 23 May 2024
Great Appearance at AANS 2024 in Chicago
Thursday, 07 Mar 2024
New article published on ArtiFascia: Neural tissue tolerance to synthetic dural mater graft implantation – read more!
Friday, 16 Feb 2024
First ArtiFascia Dura repair procedures carried out in the US
Thursday, 25 Jan 2024
Iron Nation invests in Nurami Medical
Thursday, 10 Aug 2023
ArtiFascia® Receives 510K Clearance
Tuesday, 14 Mar 2023
Nurami Medical has been accepted to the In-Ventech Growth Stage Program
Wednesday, 21 Sep 2022
Nurami Medical announces positive results from its brain surgery clinical trial
Friday, 04 Feb 2022
Nurami welcomes Peter Stebbins, its new Executive Chair of the Board
Thursday, 03 Feb 2022
Nurami Medical finishes recruitment for tissue damage clinical trial
Saturday, 08 Jan 2022
Nurami seeks FDA, EU approval for soft tissue repair solution
Thursday, 05 Nov 2020
Nurami Medical Raises $5 Million Round Led by Almeda Ventures
Saturday, 06 Jun 2020
Nurami Medical develops innovative sealants and surgical patches based on unique combinations of advanced bioactive materials and optimized, electrospun nanofiber scaffolds
Wednesday, 20 May 2020
A healing solution after brain surgery
Monday, 11 May 2020
Nurami Medical was awarded the Seal of Excellence under the Horizon 2020
Tuesday, 07 Jan 2020
ArtiFascia Pivotal NEOART study has been initiated
Tuesday, 19 Nov 2019
Nurami’s first patent was granted in the US and China
Wednesday, 15 May 2019
Henry Brem Joins Nurami Medical’s Scientific Advisory Board
Thursday, 04 Apr 2019
Nora Nseir selected among 4 finalists at the EU Woman Innovator 2019
Sunday, 06 Jan 2019
ArtiFasciaTM First-in-Human clinical study has been successfully completed
March 5-8, 2026USA
Nurami Medical attended the NASBS Annual Meeting 2026
October 11–15, 2025USA
Nurami Medical attended the Congress of Neurological Surgeons (CNS) Annual Meeting 2025
May 7-8, 2025Israel
Nurami Atttended the Israeli Neurological Society’s annual meeting
April 25-28, 2025USA
Nurami to attend AANS 2025 in Boston in April
Feb 13-16, 2025USA
Nurami to Attend NASBS 2025 in New Orleans
Oct 15 - 17, 2024Canada
Nora Nseir to Present at MedTech in Toronto
30 Sep- 2 Oct, 2024USA
Nurami will be at annual CNS congress in Houston
May 3-May 6, 2024United States
Nurami to Attend AANS 2024 in Chicago
May 08 - May 11, 2023Israel
Nurami Medical has been accepted to the In-Ventech Growth Stage Program
Sept 18 - Sept 22, 2023Spain
Nora Nseir Pitches at LSI 2023
Sept 9 - Sept 13, 2023US
Nurami made waves at CNS 2023
Oct 8- Oct 12, 2022US
Nurami Medical at CNS 2022 Annual Meeting in San Francisco
